Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein

Inclusion Criteria: * Participants over 18 years of age, regardless of race or gender * Advanced unresectable hepatocellular carcinoma with branch portal vein thrombosis (confirmed by non-invasive criteria European Association for the Study of the Liver \[EASL\]/American Association for the Study of Liver Diseases \[AASLD\], mandatory by histology in non-cirrhotic participants); can be naive or recurrent HCC after curative treatment ( \>6 months before randomization) * Unilobar disease * Child Pugh A * Tumor volume ≤70% of liver volume (determined by visual estimation) * At least one uni-dimensional HCC target lesion assessable by computed tomography (CT) or magnetic resonance imaging (MRI) according to Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 * Platelets ≥ 50\*10\^3/microliter (µL) * White blood cell (WBC) ≥1.5\*10\^3/microliter (µL) * Aspartate transaminase (AST)/ alanine aminotransferase (ALT) ≤5 times upper limit of normal * Creatinine ≤2.0 mg/deciliter (dL) * Life expectancy \>3 months * Signed informed consent Exclusion Criteria: * Confirmed extra hepatic metastases. Participants with indeterminate hepatic hilar lymph nodes up to 2.5 centimeters (cm) in greatest dimension, or with indeterminate lung nodules (single lesion between 1-1.5 cm, or multiple smaller lesions with a total diameter of ≤2 cm) may be included if metastatic disease is deemed unlikely * Known contraindicatio…